Jpmorgan Chase & CO Standard Biotools Inc. Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Standard Biotools Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 139,748 shares of LAB stock, worth $255,738. This represents 0.0% of its overall portfolio holdings.
Number of Shares
139,748
Previous 129,753
7.7%
Holding current value
$255,738
Previous $229,000
17.47%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding LAB
# of Institutions
142Shares Held
279MCall Options Held
27.2KPut Options Held
34.1K-
Casdin Capital, LLC New York, NY71.3MShares$130 Million10.68% of portfolio
-
Viking Global Investors LP58.7MShares$107 Million0.44% of portfolio
-
Black Rock Inc. New York, NY21.8MShares$39.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA17.3MShares$31.6 Million0.0% of portfolio
-
Morgan Stanley New York, NY15.2MShares$27.9 Million0.0% of portfolio
About STANDARD BIOTOOLS INC.
- Ticker LAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 78,654,800
- Market Cap $144M
- Description
- Standard BioTools Inc. creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar ...